Does a GPR119 Agonist Help Glucagon Response in Type 1 Diabetes?
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
HEC88473 (Dual GLP-1/FGF21 Agonist): First-in-Human Phase 1 Findings
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
Does SGLT2 Inhibitor Use Modify Oral Semaglutide’s Cardiovascular Benefit in Type 2 Diabetes?
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide's cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
Once-Weekly Insulin Icodec in Type 2 Diabetes: Consistent Across GLP-1RA and SGLT2i Background Therapy
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Does iGlarLixi Improve Early Blood Sugar Control in Asians with Type 2 Diabetes?
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.
REMIND-DM: Design of a Cluster-Randomised Trial of PCI-Report Reminders for Diabetes Discharge Care
REMIND-DM is the protocol and baseline description of a cluster-randomised quality improvement trial testing PCI-report reminders to boost SGLT2 inhibitor and GLP-1RA prescribing after PCI in type 2 diabetes; no outcomes are yet reported. PICO summary and expert commentary.
Trial Protocol: Can Peer-Champion Support Increase SGLT2i and GLP-1RA Prescribing in Primary Care?
A published protocol for a pragmatic cluster-randomized trial testing peer-champion interventions to increase SGLT2i and GLP-1RA prescribing in primary care, reporting design and baseline cohort only with no clinical outcomes yet. PICO summary and expert commentary.
BGM0504 in Healthy Volunteers: What a Phase I Dose-Escalation Study Found
A first-in-human Phase I dose-escalation study found the dual GLP-1/GIP receptor agonist BGM0504 was generally safe and well tolerated in 40 healthy volunteers, with dose-related weight reduction and gastrointestinal adverse events. PICO summary and expert commentary.
Ebenatide in Type 2 Diabetes: A Small Phase-2 Trial of Glycaemia and Body Fat
A 78-patient randomised placebo-controlled trial of the GLP-1 analogue Ebenatide in type 2 diabetes, with a between-group glycaemic edge at Week 24 only. PICO summary and expert commentary.
IcoSema vs Semaglutide in Type 2 Diabetes: Better HbA1c, but Weight Favours Semaglutide (COMBINE 2)
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.